recently as 1957 by Sament & Schwartz, but has subsequently been reported with everincreasing frequency, and is now believed to comprise at least 10-20% of all cases of diabetic coma (Podolsky 1978) . Even this may be an underestimate, since in a recent study of 86 episodes of diabetic coma, 28 (33%) were due to hyperosmolar coma (Keller et al. 1975) , and it is possible that many cases are unrecognized or unreported (Halmos et 01. 1966 , Podolsky 1978 . Both its diagnosis and treatment contain some notable pitfalls for the unwary, which contribute to the high mortality, and although its management is generally similar to that of diabetic ketoacidotic coma, there are several important differences of emphasis, which may influence the outcome of treatment. These differences will be highlighted in this paper.
A useful practical definition, based on the full title of the syndrome, is: those cases of diabetic coma in which the plasma osmolality exceeds 350mosm/kg, the blood glucose exceeds 40 mmol/l, and there are no ketones in the urine, usually indicating the absence of ketoacidosis (adapted from Gordon & Kabadi 1976 ). On a strict basis, there are several flaws in this definition; for example, patients are usually drowsy rather than comatose (Gerich et 01. 1971) and the absence of ketonuria may be due to renal impairment rather than lack of ketoacidosis (British Medical Journal 1965) . More significantly, the definition is dependent on whether the osmolality is actually measured by osmometry or is simply calculated from the blood urea, electrolyte and glucose levels, because the measured osmolality is usually higher than the calculated value (Tomkins & Dormandy 1971). The latter also depends on the particular formula used; for example, some authors omit the urea concentration (McCurdy 1970), and others allow for the osmolal coefficient of plasma being less than unity (Loeb 1974) . The increasing use of osmometry will lead to more uniform diagnostic criteria, although it will probably augment the number of patients classified as hyperosmolar. . The subdivision of diabetic coma into ketoacidotic and hyperosmolar coma is somewhat artificial since they probably present two ends of a continuous spectrum of clinical presentations (Foster 1974 , Alberti & Hockaday 1977 . Many patients in diabetic coma are both ketoacidotic and hyperosmolar -the two features are not mutually exclusive. However, the classification is validated not only by the different clinical features of the two extremes, but also by their different mortality rates. In most large published series of hyperosmolar coma, this has been between 40 and 60% (Arieff & Carroll 1972 , McCurdy 1970 although in some series it has been lowered to around 20% (Gerich et 01. 1971) . By contrast, the mortality of ketoacidotic coma is 5-15% (Alberti & Hockaday 1977) . Before discussing the management of hyperosmolar coma, some important factors contributing to the high mortality merit special mention.
First, there is often a critical delay in establishing the diagnosis and initiating therapy, due to its deceptive clinical presentation. Typically, the condition affects elderly or middle-aged patients who either have no previous history of diabetes or perhaps are known to be mildly diabetic. They commonly present with nonspecific drowsiness and confusion and may not initially appear to be particularly ill, partly because of the absence of Kussmaul breathing. Frequently, transient focal neurological signs lead to an erroneous diagnosis ofcerebrovascular accident (Arrieff & Carroll 1972) . Indeed, the diagnosis may be entirely missed unless the urine is tested, and it may be difficult to obtain a specimen from an incontinent and uncooperative patient. Even when glycosuria has been detected, the absence of ketonuria may mislead the admitting clinician, who may be conditioned to equate severe diabetic imbalance with ketoacidosis. After the correct diagnosis has been made, there may still be a critical lack of urgency in initial treatment because of failure to appreciate the severity of the illness (Halmos et 01. 1966 , Podolsky 1978 .
. Secondly, hyperosmolar coma is usually superimposed on other underlying or associated illnesses, which are often multiple and severe (Gerich et 01. 1971) . By contrast, any precipitating illness in ketoacidotic coma is usually mild. Sixteen out of 20 hyperosmolar coma patients reported by Gerich had multiple precipitating factors, including underlying infection in 12, but only 3 of their 10 ketoacidotic patients had an associated illness. Most deaths in hyperosmolar coma are caused by these additional factors rather than the hyperosmolar coma . perse. Thus, 19deaths were reported in a study of 33 episodes of hyperosmolar coma by Arieff & Carroll (1972) of which 15 were due to associated illnesses, notably pneumonia and gramnegative septicaemia; this high mortality occurred despite adequate correction of the dehydration and hyperglycaemia in 28 of the series. In an analysis of 84 case reports in the literature, McCurdy (1970) found that about half of the 34 deaths were due to severe preexistent and precipitating illnesses; most of the other 'deaths were due to late thromboembolism or initial severe shock.
. . i
It is clear from these data that most of the deaths in patients with hyperosmolar coma are broadly due to 'general' rather than 'diabetic' factors. However, most therapeutic endeavour tends to be concentrated on the latter. In the author's opinion, there is a very real danger that undue preoccupation with correction of the biochemistry and with the specifically diabetic aspects of management may lead to insufficient attention being paid to the all-important general aspects of management. A deliberately broad approach to clinical care is necessary to ensure that all the underlying or associated illnesses are identified, and receive prompt and vigorous treatment. In this respect, infections in general (and chest infections in particular), acute pancreatitis, renal failure and myocardial infarction merit special attention. Clinical factors are more important to eventual outcome than biochemical factors, and the maxim 'treat the patient, not the results' is eminently applicable to this syndrome.
Two controversial aspects of general management may be briefly mentioned. Firstly, should prophylactic antibiotics be given? Accurate bacteriological diagnosis of early infection in general (and again especially chest infections), may be difficult or impossible in severely ill patients, and in view of the high incidence of underlying serious infections in hyperosmolar coma (Gerich et al. 1971) and their effect on prognosis (Arieff & Carroll 1972), the case for prophylactic antibiotics seems overwhelming. However, it is important to take all appropriate microbiological specimens before commencing therapy. Since gram-negative organisms are often incriminated in these life-threatening severe infections (Arieff & Carroll 1972), broadspectrum antibiotics are indicated and a suitable combination would be gentamicin and benzylpenicillin. The dose of gentamicin must take into account any renal impairment, and blood levels should be monitored.
Secondly, should anticoagulant therapy be given? These patients occasionally develop arterial thromboses (Pyke 1969) , especially following hypotensive episodes (Whelton et al. 197I, Halmos et al, 1966) , and a significant number of late deaths are caused by pulmonary embolism (McCurdy 1970 , Keller et al. 1975 . Some authors have therefore suggested the use of prophylactic heparin (Halmos et al. 1966 , Alberti & Nattrass 1978 , although others have wamed of the rare occurrence of gastrointestinal bleeding secondary to erosive gastritis (Keller et 01. 1975) . Low dose subcutaneous heparin is remarkably free from troublesome side effects and is unlikely to cause either severe gastrointestinal haemorrhage or undue bleeding around venepuncture and infusion sites. In view of its excellent results in prophylaxis against deep venous thrombosis in other clinical situations its use in hyperosmolar coma seems justified, although as yet there are no clinical data to indicate how effective it will be.
Fluid replacement: The rate of infusion of intravenous fluids in the initial stages of treatment requires careful judgment, and constitutes one of the major problems of management. On the one hand, hyperosmolar coma patients have a greater fluid deficit than ketoacidotic patients (Gerich et 01. 1971 ,Arieff& Carroll 1972 ,due to the longer duration of the prodromal osmotic diuresis (McCurdy 1970 , Gerich et 01. 1971 and they therefore require more replacement fluids in total. However, the patient's increased age, the likelihood of ischaemic heart disease, the commonly associated renal impairment (Arieff & Carroll 1972) and the occasional occurrence of unexplained circulatory failure following severe diabetic coma (Keller et 01. 1975) , will all predispose to circulatory overload and pulmonary oedema if large volumes of fluid are infused too quickly. Furthermore, too rapid correction of the dehydration and hyperosmolality may produce dangerous osmotic disequilibria (Alberti & Nattrass 1978) . Thus the optimum rate of fluid replacement is a compromise between these opposing factors and varies considerably from patient to patient. There is no single fluid regimen suitable for all patients; each patient's infusion rota needs to be individually planned, taking into account his cardiac, circulatory and renal status. Many quoted regimens for diabetic coma are designed for younger ketoacidotic patients, and may be far too vigorous in this clinical context. Central venous pressure monitoring is mandatory, because of the ever-present risk of circulatory overload. Initially, rapid fluid replacement is often necessary to restore blood pressure, tissue perfusion and urine output, but after any acute hypovolaemia has been adequately treated, fluids should be administered cautiously. Frequent careful reassessment of fluid balance is fundamental to successful management: perhaps even more so than frequent reassessment of the biochemical profile.
The type of intravenous fluid solution to be infused remains controversial. Many authorities advocate the use of hypotonic (0.45%) saline in all cases (Gerich et 01. 1971), Arieff & Carroll 1972 , Podolsky 1978 , Malins 1971 , whereas others recommend isotonic (0.9%) saline unless the plasma sodium concentration exceeds 155 mmol/l, when hypotonic (0.45%) saline is again advocated (Alberti & Nattrass 1978 , Gordon & Kabadi 1976 . There are no satisfactory clinical trials comparing the two solutions, so choice is based largely on theoretical considerations. At first sight, it would seem logical to use hypotonic saline, since the fluid lost in the prodromal osmotic diuresis is also hypotonic, and indeed has an approximately similar tonicity (Arietf & Carroll 1972) . In addition, the use of hypotonic saline will largely prevent the further rise in plasma sodium often seen during initial infusion of isotonic saline, il"nd will lead to a more rapid correction of both the hyperosmolality and any hypernatraemia. However, the increase in plasma sodium with isotonic saline infusion is not dangerous in this situation, because concurrently the plasma osmolality is usually falling, due to a rapid decrease in blood glucose concentration; the hypernatraemia thus acts as a buffer, preventing too rapid a fall in osmolality, and possible cerebral oedema (Alberti & Hockaday 1977) .
Cerebral oedema is a serious and usually fatal complication of the treatment of diabetic coma which is thought to occur when the hyperosmolality and hyperglycaemia are corrected too quickly by hypotonic fluids and insulin therapy, leading to a temporary osmotic gradient across cell membranes; water is then diverted intracellularly producing swelling of the brain -cerebral oedema (Arietf & Kleeman 1974). Although principally described in the treatment of ketoacidosis (Young & Bradley 1967 , Duck et 01. 1976 , it has also been recorded during the treatment of hyperosmolar coma (Fernandez et 01. 1968, Maccario and Messis 1969) and although it is infrequently reported in the literature, minor degrees may be more common than is generally realized (Alberti & Hockaday 1977) . For example, a paradoxical increase in drowsiness is occasionally observed during the first few hours of treatment in relatively mild cases of diabetic coma. This has been shown to be associated with a rise of cerebrospinal fluid Journal ofthe Royal Society ofMedicine Volume 73February 1980 /37 pressure in young ketoacidotic patients (Clements et 01. 1971) and may be due to cerebral oedema, although other studies in hyperosmolar coma have failed to confirm this (Arieff & Carroll 1972) . Cerebral oedema is also a well recognized complication of hypotonic fluid therapy in the closely analogous situation of the treatment of severe hypernatraemia in grossly dehydrated infants (Haddow & Cohen 1974) . Thus, although fatal cerebral oedema is rare, it is nevertheless a significant and dangerous complication of treatment of hyperosmolar coma, and is associated with the use of hypotonic fluids. Because of this, the use of hypotonic saline should be avoided, and isotonic saline is the fluid therapy of choice, regardless of the plasma sodium concentration. Admittedly, this increases the risk of sodium overload and circulatory failure, but this may be avoided by careful fluid balance, with central venous pressure monitoring and slow correction of the fluid deficit.
Insulin therapy is usually administered as in the treatment of diabetic ketoacidosis. Low-dose insulin regimens are now generally regarded as more logical, equally effective and possibly safer than the older high-dose regimens (Alberti & Nattrass 1978) although as yet there is no evidence of any beneficial effect on prognosis. In practice, there is little to choose between the different routes of giving low-dose insulin (Kitabchi et al. 1976) . Although intravenous infusion techniques have slight theoretical advantages (such asdecreased risk of hypo glycaemia and perhaps also of hypokalaemia), they are rather more vulnerable to human error, and low-. dose intramuscular regimens may be safer and similarly effective. In fact, insulin therapy is not always essential in the management of hyperosmolar coma; in certain patients, endogenous insulin production may be quite adequate following rehydration, and no exogenous insulin is necessary (Hayes & Woods 1968 , Gerich et 01. 1971 . Insulin therapy is usually given nevertheless, but it is far less important in this situation than either the fluid therapy or the treatment of underlying/associated illnesses. There is perhaps a risk that the current interest in different techniques of insulin delivery may distract attention away from these more vital aspects of management.
Potassium replacement is again similar to that employed in the treatment of diabetic ketoacidosis. Over the past decade there has been increasing awareness of the dangers of a profound and potentially fatal fall in plasma potassium concentration to levels below 2.0 mrnol/l, following insulin therapy (Watkins et al. 1970 , Abramson & Arky 1966 , especially when the initial level is rather low, say 3.0-3.5 mmol/l. Earlier and more vigorous potassium therapy is now generally and wisely advocated (Alberti & Nattrass 1978 , Podolsky 1978 , even to the extent of adding potassium to the infusion fluids before the plasma level is known, in severely ill patients (Malins 1971) . In hyperosmolar coma, the initial potassium level tends to be slightly lower than in ketoacidosis (McCurdy 1970) , both because of the absence of marked acidosis and because the net potassium losses may be even more profound (Podolsky & Emerson 1973) . The risk of inducing a precipitous and dangerous fall in plasma potassium with insulin therapy is therefore even greater in hyperosmolar coma. Since insulin is not essential in the initial management, our policy is therefore to withhold insulin until the plasma potassium level is available from the laboratory, and is known to exceed 4.0 mmol/l. If lower than this, large amounts of potassium (26-52 mrnol/hour) are added to the infusion fluids to elevate the plasma level before any insulin is given. In this way, the threat of fatal hypokalaemia can safely be averted. After the acute episode it is wise policy to administer oral potassium supplements for at least one week to help to restore the massive (400-1000 mmol) net potassium deficit (Ionescu-Tirgoviste & Mincu 1976) and to prevent late hypokalaemia.
Conclusions
Hyperosmolar coma is relatively common and has a high mortality, which is partly because its deceptive clinical presentation often leads to delay and lack of urgency in diagnosis and treatment. Since most deaths are due to underlying or associated illnesses rather than the metabolic disturbance perse, greater emphasis should be placed on their treatment and on the general aspects of clinical care, and less on correction of the biochemical abnormalities. The use of prophylactic antibiotics and low-dose subcutaneous heparin therapy are probably justified in all cases. Isotonic (0.9%) saline is the infusion fluid of choice regardless of the plasma sodium concentration, and hypotonic (0.45%) saline should not be given. Insulin therapy is not essential and should be withheld until the plasma potassium level is known to exceed 4.0 mmol/1. With greater awareness of its many pitfalls of diagnosis and treatment, some or many of the deaths occurring in patients with hyperosmolar coma may be averted.
